William Beaumont Army Medical Center, Department of Surgery, Fort Bliss, Texas.
Madigan Army Medical Center, Department of Surgery, Fort Lewis, Washington.
J Surg Res. 2022 Aug;276:261-271. doi: 10.1016/j.jss.2022.03.006. Epub 2022 Apr 7.
Hepatocellular carcinoma (HCC) is rare among adolescent and young adult (AYA) patients, and resection or transplant remains the only curative therapy. The role of lymph node (LN) sampling is not well-defined. The aim of this study was to describe practice patterns, as well as investigate the impact of LN sampling on survival outcomes in this population.
A retrospective cohort study using the 2004-2018 National Cancer Database (NCDB) was performed. Patients ≤21 y old with nonmetastatic HCC who underwent liver resection or transplant were evaluated. Clinical features of patients who underwent LN sampling were compared to those who did not, and univariable and multivariable logistic regression was performed to evaluate independent predictive factors of node positivity. Survival analysis was performed using Kaplan-Meier methods and Cox Proportional Hazard Survival Regression.
A total of 262 AYA patients with HCC were identified, of whom 137 (52%) underwent LN sampling, 44 patients had positive nodes, 40 (95%) of them had tumors >5 cm; 87 (64%) of patients with sampled nodes had fibrolamellar carcinoma (FLC), which was an independent risk factor for predicting positive nodes (P = 0.001). There was no difference in overall survival between patients who underwent LN sampling and those who did not; however, 5-y overall survival for node-positive patients was 40% versus 79% for node-negative patients (P < 0.0001).
In AYA patients with HCC, LN sampling was not associated with an independent survival benefit. However, FLC was an independent risk factor for LN positivity, suggesting a role for routine LN sampling in these patients.
肝细胞癌(HCC)在青少年和年轻成人(AYA)患者中较为罕见,且切除术或移植仍是唯一的治愈性治疗方法。淋巴结(LN)取样的作用尚未明确。本研究旨在描述实践模式,并探讨该人群中 LN 取样对生存结果的影响。
采用 2004 年至 2018 年国家癌症数据库(NCDB)进行回顾性队列研究。评估了≤21 岁且患有非转移性 HCC 并接受肝切除术或移植的患者。比较了行 LN 取样患者的临床特征与未行 LN 取样患者的临床特征,并进行单变量和多变量逻辑回归分析,以评估淋巴结阳性的独立预测因素。采用 Kaplan-Meier 方法和 Cox 比例风险生存回归进行生存分析。
共确定了 262 例 HCC 的 AYA 患者,其中 137 例(52%)行 LN 取样,44 例有阳性淋巴结,40 例(95%)肿瘤>5cm;87 例(64%)有取样淋巴结的患者患有纤维板层样癌(FLC),这是预测阳性淋巴结的独立危险因素(P=0.001)。行 LN 取样的患者与未行 LN 取样的患者的总体生存率无差异;然而,淋巴结阳性患者的 5 年总体生存率为 40%,而淋巴结阴性患者的 5 年总体生存率为 79%(P<0.0001)。
在 HCC 的 AYA 患者中,LN 取样与独立生存获益无关。然而,FLC 是 LN 阳性的独立危险因素,提示在这些患者中常规行 LN 取样有一定作用。